By Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab,...

By Daniella Parra Avertix Medical said it was collaborating with the Heart & Rhythm Institute of Trinity to bring an FDA-approved implantable heart attack detection and warning system to patients with high-risk coronary disease, it said. The implant, called the...

By Daniella Parra Sparrow Pharmaceuticals said it was extending the trial phase for SPI-62, a potential treatment for ACTH-dependent Cushing’s syndrome. The goal is to gather new long-term safety and tolerability data, with continued monitoring of SPI-62’s effects on signs...

  Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, presented promising outcomes from the ReSPECT-LM clinical study at the SNO/ASCO CNS Cancer Conference. The study assesses rhenium (186Re) obisbemeda’s effectiveness in treating leptomeningeal metastases (LM), it said. Rhenium (186Re)...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said early clinical data demonstrated a trend for slowing cognitive decline in mild Alzheimer’s disease for its UB-311 vaccine. The Phase 2a study, conducted in Taiwan showed that UB-311 offers advantages such as lower...

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), said it enhanced its SQore platform with four new patents and two notices of allowance. The additions, spanning the U.S., Canada, South Korea and India, will strengthen the proprietary viscosity-reducing...

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said it completed a $4.1 million private placement of shares and warrants to existing stockholders. The company said it aims to develop new biologic medicines to improve patient access and...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it appointed Peter Powchik, M.D. as Executive Vice President, Global Scientific Director overseeing its scientific direction and lead development efforts. Powchik was previously Senior Vice President at Regeneron Pharmaceuticals, the company said....

By Daniella Parra Plus Therapeutics (Nasdaq: PSTV) said it appointed Dr. Pius Maliakal as VP of Clinical Operations. With over 20 years of global oncology experience, he will lead key clinical initiatives, advancing the ReSPECT-GBM and ReSPECT-LM trials for central...

By Daniella Parra Octave Bioscience said it secured a $30 million extension to its Series B funding round. The investment, led by Novartis, Hikma Ventures and Intermountain Ventures, will accelerate commercialization of their precision care solution for multiple sclerosis (MS)...